<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345928</url>
  </required_header>
  <id_info>
    <org_study_id>CR105130</org_study_id>
    <secondary_id>CNTO7160ASH1001</secondary_id>
    <secondary_id>2014-000633-23</secondary_id>
    <nct_id>NCT02345928</nct_id>
  </id_info>
  <brief_title>A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Ascending Dose Study of CNTO 7160 in Subjects With Asthma and Subjects With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of single ascending dose
      of CNTO 7160 administered intravenously (IV) in healthy participants and multiple dose
      administered IV in participants with asthma and atopic dermatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, randomized, placebo-controlled, multicenter study of CNTO 7160. The study
      consists of Screening Period, In-patient period (6 days for healthy participants, 11 days for
      asthmatic participants and atopic dermatitis participants) and outpatient period (105 days
      for healthy participants, 110 days for asthmatic and atopic dermatitis participants). The
      total duration of participation for each participant will be approximately 21 weeks for
      healthy participants, 25 weeks for asthmatic participants, and atopic dermatitis
      participants. All eligible participants will be randomly assigned to receive active agent or
      placebo. The study will be conducted in 2 parts. In Part 1, single ascending doses of CNTO
      7160 or placebo will be administered to sequential cohorts of healthy participants as an IV
      infusion. In Part 2, ascending multiple doses of CNTO 7160 or placebo will be administered as
      IV infusions to sequential cohorts of participants with asthma or atopic dermatitis. Blood
      samples will be collected for assessment of pharmacokinetic and pharmacodynamics parameters
      in both part 1 and 2 parameters, along with assessment of safety and clinical effects in part
      2. Participants' safety will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2014</start_date>
  <completion_date type="Actual">March 16, 2017</completion_date>
  <primary_completion_date type="Actual">March 16, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability of CNTO 7160 (Part 1)</measure>
    <time_frame>Through Week 17</time_frame>
    <description>The incidence of TEAEs from treatment until the last scheduled follow-up visit will be summarized by treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability of CNTO 7160 (Part 2)</measure>
    <time_frame>Through Week 21</time_frame>
    <description>The incidence of TEAEs from treatment until the last scheduled follow-up visit will be summarized by treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) (Part 1)</measure>
    <time_frame>Up to Week 17 after dose</time_frame>
    <description>Cmax (microgram per millileter [mcg/mL]) will be summarized by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) (Part 2)</measure>
    <time_frame>Up to Week 21 after dose</time_frame>
    <description>Cmax (mcg/mL) after the first and last dose will be summarized by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Time Curve [AUC(0-t) and AUC(0-infinity)] (Part 1)</measure>
    <time_frame>Up to Week 17 after dose</time_frame>
    <description>AUC (mcg*day/mL) will be summarized by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration Versus Time Curve [AUC(t1-t2)] (Part 2)</measure>
    <time_frame>Up to Week 21 after dose</time_frame>
    <description>AUC (mcg*day/mL) will be summarized by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Antibodies to CNTO 7160 (Part 1)</measure>
    <time_frame>Up to Week 17</time_frame>
    <description>The incidence of participants with anti-CNTO 7160 antibodies will be summarized by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Antibodies to CNTO 7160 (Part 2)</measure>
    <time_frame>Up to Week 21</time_frame>
    <description>The incidence of participants with anti-CNTO 7160 antibodies will be summarized by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Immunoglobulin E (IgE) (Part 2)</measure>
    <time_frame>Baseline, Week 21</time_frame>
    <description>Change from Baseline in immunoglobulin E (IgE) Concentration (international unit per millileter [IU/mL]) through Week 21 will be summarized by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Chemokine (C-C motif) Ligand 17 (CCL17) (Part 2)</measure>
    <time_frame>Baseline, Week 21</time_frame>
    <description>Change from Baseline in Chemokine (C-C motif) Ligand 17 (CCL17) concentration (picogram per millileter [pg/mL]) through Week 21 will be summarized by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 second (FEV1) in Participants With Asthma</measure>
    <time_frame>Baseline Up to week 21</time_frame>
    <description>Changes in FEV1 (liter [L]) from baseline through end of follow up will be summarized by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eczema Area Severity Index (EASI) in Participants With Atopic Dermatitis</measure>
    <time_frame>Baseline up to week 21</time_frame>
    <description>Changes in EASI score from baseline through the end of follow up will be summarized by treatment group.</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Asthma</condition>
  <condition>Atopic Dermatitis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO7160 or Placebo administered IV infusion Dose 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO7160 or Placebo administered IV infusion Dose 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO7160 or Placebo administered IV infusion Dose 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO7160 or Placebo administered IV infusion Dose 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO7160 or Placebo administered IV infusion Dose 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO7160 or Placebo administered IV infusion Dose 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO7160 or Placebo administered IV infusion Dose 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO7160 or Placebo administered IV infusion Dose 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO7160 or Placebo administered IV infusion Dose 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Asthma): Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Asthma): Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Atopic Dermatitis): Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Atopic Dermatitis): Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1: CNTO 7160</intervention_name>
    <description>Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg).</description>
    <arm_group_label>Part 1: Dose 1</arm_group_label>
    <arm_group_label>Part 1: Dose 2</arm_group_label>
    <arm_group_label>Part 1: Dose 3</arm_group_label>
    <arm_group_label>Part 1: Dose 4</arm_group_label>
    <arm_group_label>Part 1: Dose 5</arm_group_label>
    <arm_group_label>Part 1: Dose 6</arm_group_label>
    <arm_group_label>Part 1: Dose 7</arm_group_label>
    <arm_group_label>Part 1: Dose 8</arm_group_label>
    <arm_group_label>Part 1: Dose 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2 (Asthma): CNTO 7160</intervention_name>
    <description>Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).</description>
    <arm_group_label>Part 2 (Asthma): Dose 1</arm_group_label>
    <arm_group_label>Part 2 (Asthma): Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2 (Atopic Dermatitis): CNTO 7160</intervention_name>
    <description>Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).</description>
    <arm_group_label>Part 2 (Atopic Dermatitis): Dose 1</arm_group_label>
    <arm_group_label>Part 2 (Atopic Dermatitis): Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1 and Part 2: Placebo</intervention_name>
    <description>Participants will receive single IV infusion of placebo matched to CNTO 7160.</description>
    <arm_group_label>Part 1: Dose 1</arm_group_label>
    <arm_group_label>Part 1: Dose 2</arm_group_label>
    <arm_group_label>Part 1: Dose 3</arm_group_label>
    <arm_group_label>Part 1: Dose 4</arm_group_label>
    <arm_group_label>Part 1: Dose 5</arm_group_label>
    <arm_group_label>Part 1: Dose 6</arm_group_label>
    <arm_group_label>Part 1: Dose 7</arm_group_label>
    <arm_group_label>Part 1: Dose 8</arm_group_label>
    <arm_group_label>Part 1: Dose 9</arm_group_label>
    <arm_group_label>Part 2 (Asthma): Dose 1</arm_group_label>
    <arm_group_label>Part 2 (Asthma): Dose 2</arm_group_label>
    <arm_group_label>Part 2 (Atopic Dermatitis): Dose 1</arm_group_label>
    <arm_group_label>Part 2 (Atopic Dermatitis): Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1 (Healthy Participants): Participant must have a body weight in the range of 50
             to 100 kilogram (kg) inclusive and have a body mass index (BMI) of 19 to 30 kilogram
             per meter square (kg/m^2) inclusive

          -  Part 1 (Healthy Participants): Participant must be healthy on the basis of physical
             examination, medical history, vital signs and 12-lead ECG performed at screening

          -  Part 2 (Asthma Participants): Participant must have a body weight in the range of 50
             to 125 kg inclusive and have a BMI of 19 to 32 kg/m^2 inclusive

          -  Part 2 (Asthma Participants): Participant must have a physician documented diagnosis
             of asthma for at least 12 months before screening

          -  Part 2 (Atopic Dermatitis Participants): Participant must have a body weight in the
             range of 50 to 100 kg inclusive and have a BMI of 19 to 30 kg/m^2 inclusive

          -  Part 2 (Atopic Dermatitis Participants): Participant has physician documented
             diagnosis of atopic dermatitis for at least 12 months before screening based on UK
             refinements of the Rajka and Hanifin criteria

        Exclusion Criteria:

          -  Part 1 (Healthy Participants): Participant has any known malignancy or history of
             malignancy, with the exception of basal cell carcinoma or squamous cell carcinoma in
             situ of the skin that has been treated with no evidence of recurrence within 6 months
             prior to the Screening Visit

          -  Part 1 (Healthy Participants): Participant currently has or has a history of any
             clinically significant cardiovascular disease, including but not limited to a history
             of angina or myocardial infarction, congestive heart failure, symptomatic
             atherosclerotic vascular disease, or arrhythmia.

          -  Part 2 (Asthma Participants): Participant has any known malignancy or history of
             malignancy, with the exception of basal cell carcinoma or squamous cell carcinoma in
             situ of the skin that has been treated with no evidence of recurrence within 6 months
             prior to the Screening Visit

          -  Part 2 (Asthma Participants): Participant has or have had a serious infection (eg,
             sepsis, pneumonia or pyelonephritis), or have been hospitalized or received IV
             antibiotics for a serious infection during the 4 months prior to the Screening Visit

          -  Part 2 (Atopic Dermatitis Participants): Participant has any known malignancy or
             history of malignancy, with the exception of basal cell carcinoma or squamous cell
             carcinoma in situ of the skin that has been treated with no evidence of recurrence
             within 6 months prior to the Screening Visit.

          -  Part 2 (Atopic Dermatitis Participants): Participant has or have had a serious
             infection (eg, sepsis, pneumonia or pyelonephritis), or have been hospitalized or
             received IV antibiotics for a serious infection during the 4 months prior to the
             Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>MÃ¶nchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2014</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>CNTO 7160</keyword>
  <keyword>Healthy</keyword>
  <keyword>Asthma</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

